Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Gutterman

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Cancer Genetics and Cytogenetics|August 1, 1987
Molecular characteristics of chronic myelogenous leukemia in blast crisisM Blick, P Romero, M Talpaz, et al.
JAMA|March 8, 1976
Late intensification therapy for acute leukemia in remission. Chemotherapy and immunotherapyG P Bodey, E J Freireich, E Gehan, et al.
Acta Haematologica|January 1, 1987
Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemiaH M Kantarjian, M Talpaz, R Kurzrock, et al.
Leukemia|January 1, 1987
Hematologic response of four patients with smoldering acute myelogenous leukemia to partially pure gamma interferonM Beran, B Andersson, H Kantarjian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 1999
Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award LectureH M Kantarjian, M Talpaz, S O'Brien, et al.
Blood|January 1, 1990
Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemiaR Mashal, M Shtalrid, M Talpaz, et al.
Blood|May 1, 1992
Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSFE Estey, P F Thall, H Kantarjian, et al.
Blood|February 15, 1992
Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemiaH M Kantarjian, E H Estey, S O'Brien, et al.
Bone Marrow Transplantation|January 1, 1993
Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantationC Ippoliti, D Przepiorka, S Giralt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1989
Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I studyK H Lee, M Talpaz, J M Rothberg, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Cancer Genetics and Cytogenetics|August 1, 1987
Molecular characteristics of chronic myelogenous leukemia in blast crisisM Blick, P Romero, M Talpaz, et al.
JAMA|March 8, 1976
Late intensification therapy for acute leukemia in remission. Chemotherapy and immunotherapyG P Bodey, E J Freireich, E Gehan, et al.
Acta Haematologica|January 1, 1987
Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemiaH M Kantarjian, M Talpaz, R Kurzrock, et al.
Leukemia|January 1, 1987
Hematologic response of four patients with smoldering acute myelogenous leukemia to partially pure gamma interferonM Beran, B Andersson, H Kantarjian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 1999
Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award LectureH M Kantarjian, M Talpaz, S O'Brien, et al.
Blood|January 1, 1990
Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemiaR Mashal, M Shtalrid, M Talpaz, et al.
Blood|May 1, 1992
Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSFE Estey, P F Thall, H Kantarjian, et al.
Blood|February 15, 1992
Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemiaH M Kantarjian, E H Estey, S O'Brien, et al.
Bone Marrow Transplantation|January 1, 1993
Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantationC Ippoliti, D Przepiorka, S Giralt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1989
Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I studyK H Lee, M Talpaz, J M Rothberg, et al.
Pageof 6